An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity

References

• Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642.
   PubMed Web of Science ®Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of Obesity Among Adults and Youth: United States, 2015–2016. NCHS Data Brief. 2017;(288):1–8. See https://www.cdc.gov/nchs/products/databriefs/db288.htm
   Google Scholar
• Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA. 2003;289(2):187–193.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–S138.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(7):842–884.
   PubMed Web of Science ®Google Scholar
• Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, weight watchers, and zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43–53.
   PubMed Web of Science ®Google Scholar
• Gudzune KA, Doshi RS, Mehta AK, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med. 2015;162(7):501–512.
   PubMed Web of Science ®Google Scholar
• BELVIQ. Lorcaserin hydrochloride [package insert]. Zofingen, Switzerland: Arena Pharmaceuticals; 2014.
   Google Scholar
• Tenuate. Diethylpropion hydrochloride [package insert]. Bridgewater (NJ): Aventis Pharmaceuticals; 2003.
   Google Scholar
• Suprenza. Phentermine hydrochloride [package insert]. Cranford (NJ): Akrimax Pharmaceuticals; 1959.
   Google Scholar
• Bontril. Phendimetrazine tartrate [package insert]. Princeton (NJ): Sandoz Inc.; 1982.
   Google Scholar
• Didrex. Benzphetamine hydrochloride [package insert]. New York, NY: Pfizer Inc.; 2010.
   Google Scholar
• U.S. Food & Drug Administration. FDA announces withdrawal fenfluramine and dexfenfluramine (Fen-Phen); 1997. Available from: www.fda.gov
   Google Scholar
• U.S. Food & Drug Administration. FDA drug safety communication: FDA recommends against the continued use of meridia (sibutramine). Maryland (US): Food & Drug Administration; 2010. [cited 2019 Jul 2].
   Google Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843–854.
   PubMed Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–2434.
   PubMed Web of Science ®Google Scholar
• MacLean PS, Rothman AJ, Nicastro HL, et al. The Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) core measures project: rationale and approach. Obesity (Silver Spring). 2018;26(Suppl 2):S6–S15.
   PubMedGoogle Scholar
• Donovan MH, Tecott LH. Serotonin and the regulation of mammalian energy balance. Front Neurosci. 2013;7:36.
   PubMed Web of Science ®Google Scholar
• Burke LK, Heisler LK. 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol. 2015;27(6):389–398.
   PubMed Web of Science ®Google Scholar
• Berglund ED, Liu C, Sohn JW, et al. Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis. J Clin Invest. 2013;123(12):5061–5070.
   PubMed Web of Science ®Google Scholar
• D’Agostino G, Lyons D, Cristiano C, et al. Nucleus of the solitary tract serotonin 5-HT2C receptors modulate food intake. Cell Metab. 2018;28(4):619–630.e615.
   PubMed Web of Science ®Google Scholar
• Qiu J, Fang Y, Ronnekleiv OK, et al. Leptin excites proopiomelanocortin neurons via activation of TRPC channels. J Neurosci. 2010;30(4):1560–1565.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yao T, Deng Z, et al. TrpC5 mediates acute leptin and serotonin effects via Pomc neurons. Cell Rep. 2017;18(3):583–592.
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Powell AG, Apovian CM. Emerging pharmacotherapy for obesity. Expert Opin Emerg Drugs. 2011;16(3):587–596.
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–588.
   PubMed Web of Science ®Google Scholar
• Higgins GA, Zeeb FD, Fletcher PJ. Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists. J Psychopharmacol. 2017;31(11):1403–1418.
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(4):245–256.
   PubMedGoogle Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–1436.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107–1117.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Scirica BM, Inzucchi SE, et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018;392(10161):2269–2279.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bohula EA, Dwyer JP, et al. Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial. Circulation. 2019;139(3):366–375.
   PubMed Web of Science ®Google Scholar
• Shukla AP, Kumar RB, Aronne LJ. Lorcaserin HCl for the treatment of obesity. Expert Opin Pharmacother. 2015;16(16):2531–2538.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Shanahan W, Fain R, et al. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgrad Med. 2016;128(6):591–597.
   PubMed Web of Science ®Google Scholar
• Smith SR, O’Neil PM, Astrup A, et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring). 2014;22(10):2137–2146.
   PubMed Web of Science ®Google Scholar
• Magkos F, Nikonova E, Fain R, et al. Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus. Obesity (Silver Spring). 2017;25(5):842–849.
   PubMed Web of Science ®Google Scholar
• Smith SR, Garvey WT, Greenway FL, et al. Coadministration of lorcaserin and phentermine for weight management: a 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017;25(5):857–865.
   PubMed Web of Science ®Google Scholar
• Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560–567.
   PubMed Web of Science ®Google Scholar
• Weissman NJ, Smith SR, Fain R, et al. Effects of lorcaserin on pre-existing valvulopathy: a pooled analysis of phase 3 trials. Obesity (Silver Spring). 2017;25(1):39–44.
   PubMed Web of Science ®Google Scholar
• Shram MJ, Schoedel KA, Bartlett C, et al. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther. 2011;89(5):683–692.
   PubMed Web of Science ®Google Scholar
• Farr OM, Upadhyay J, Gavrieli A, et al. Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo- controlled, double-blind clinical trial. Diabetes. 2016;65(10):2943–2953.
   PubMed Web of Science ®Google Scholar
• Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6(5):398–405.
   PubMed Web of Science ®Google Scholar
• Burke LK, Ogunnowo-Bada E, Georgescu T, et al. Lorcaserin improves glycemic control via a melanocortin neurocircuit. Mol Metab. 2017;6(10):1092–1102.
   PubMed Web of Science ®Google Scholar
• Chukir T, Shukla AP, Saunders KH, et al. Pharmacotherapy for obesity in individuals with type 2 diabetes. Expert Opin Pharmacother. 2018;19(3):223–231.
   PubMed Web of Science ®Google Scholar
• Neff LM, Broder MS, Beenhouwer D, et al. Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity. Clin Obes. 2017;7(6):337–346.
   PubMed Web of Science ®Google Scholar
• Umashanker D, Shukla AP, Saunders KH, et al. Is obesity the new hypertension? Parallels in the evolution of obesity and hypertension as recognized disease states. Curr Atheroscler Rep. 2017;19(8):35.
   PubMed Web of Science ®Google Scholar
• Tuccinardi D, Farr OM, Upadhyay J, et al. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: a six-month, randomized, placebo- controlled, double-blind clinical trial. Diabetes Obes Metab. 2019;21(6):1487–1492.
   PubMed Web of Science ®Google Scholar
• Pogorelov VM, Rodriguiz RM, Cheng J, et al. 5-HT2C agonists modulate schizophrenia-like behaviors in mice. Neuropsychopharmacol. 2017;42(11):2163–2177.
   PubMed Web of Science ®Google Scholar
• Neelakantan H, Holliday ED, Fox RG, et al. Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. ACS Chem Neurosci. 2017;8(5):1065–1073.
   PubMed Web of Science ®Google Scholar
• Harvey-Lewis C, Li Z, Higgins GA, et al. The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. Neuropharmacology. 2016;101:237–245.
   PubMed Web of Science ®Google Scholar
• Zeeb FD, Higgins GA, Fletcher PJ. The serotonin 2C receptor agonist lorcaserin attenuates intracranial self-stimulation and blocks the reward-enhancing effects of nicotine. ACS Chem Neurosci. 2015;6(7):1231–1240.
   PubMed Web of Science ®Google Scholar